Axillary Hyperhidrosis Market Size, Share & Trends Analysis and Forecast 2020-2030
All the vital news, analysis, and commentary curated by our industry experts.
The axillary hyperhidrosis (AH) market in the US has been valued at $65.6 million in 2020 and is projected to grow at a CAGR of more than 15% during the period 2021-2025. The sales of high-priced neuromuscular blockades represent the most impactful driver of growth for the AH market, but limited disease awareness will remain the main barrier and will keep diagnosis and treatment of cases at a low rate. The impacts of the COVID-19 pandemic have limited the size of the AH market for 2020, with reduced social pressures causing fewer symptoms of AH in diagnosed individuals, combined with fear of office visits and in-office procedures during a pandemic. Thus, the market has shown signs of recovery in late 2020 through 2021.
A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are antiperspirants, anticholinergics, and neuromuscular blockades. Currently, there are only two treatments that are found to be FDA-approved for the symptomatic management of AH, Journey Medical Corporation’s Qbrexza (glycopyrronium tosylate) and Allergan’s Botox (onabotulinumtoxin A). In addition, MiraDry system is the first novel, non-invasive, long-lasting medical device FDA-approved for AH.
Overview of the axillary hyperhidrosis market
For more insights on this report, download a free report sample
What are the trends in the axillary hyperhidrosis (AH) market?
The sales of high-priced neuromuscular blockades represent the most impactful driver of growth for the AH market. The launch of Ecclock (sofpironium bromide) in Q4 2022 has shown a positive impact on total sales. Patient motivation and high compliance with prescribed treatments have improved the sales and the lack of generic options for all marketed products increases revenue, with the first generic entry not coming until the end of the forecast period.
The lifetime diagnosed prevalent cases of axillary hyperhidrosis are expected to increase in the US by 0.42% between 2020 and 2030. The women made up roughly 60% of lifetime diagnosed prevalent cases of axillary hyperhidrosis in the US and due to a lack of temporal data, changes in the number of lifetimes diagnosed prevalent cases throughout the forecast can be attributed to changes in the underlying population structure of the US.
The lifetime diagnosed prevalent cases in the US in 2020 has peaked in the 20–29-year age group and gradually declined afterward through the 50–59-year age group before significantly dropping in the 60–69, 70–79, and ≥80-year age groups. Therefore, the distribution of cases by age is expected to remain similar throughout the forecast period.
Age-specific prevalence of axillary hyperhidrosis (AH), 2020
For more insights, download a free report sample
How many drugs are approved for AH in the market?
There were only two marketed drugs for AH in 2020: Qbrexza, the first-in-class reformulation of an anticholinergic; and Botox, a first-in-class neuromuscular blockade. An additional anticholinergic reformulation, Ecclock (sofpironium gel), is expected to be launched in the market. Glycopyrronium tosylate generic wipes are also expected to launch by the end of the forecast period.
What is the treatment for axillary hyperhidrosis?
The first line of treatment for AH is the use of topical antiperspirants such as the prescription products Drysol, Hypercare, and Xerac AC or clinical-strength OTC products.
Prescription cloth wipes
Qbrexza (glycopyrronium) wipes are a more recent option for AH treatment in patients ages nine years and older. Qbrexza is an anticholinergic drug available used for topical administration.
Botulinum toxin injections
For patients who are non-responsive or intolerant to topical therapies, Botox (onabotulinumtoxinA) injections are one of the next lines of treatment. Botox injections are a minimally invasive treatment option with an average duration of improvement of four to six months when administered to the axillae.
Off-label use of licensed oral systemic medications, including anticholinergics (glycopyrrolate, oxybutynin, benztropine, and propantheline) and beta-blockers (propranolol), may be used to treat AH. However, oral anticholinergic drugs are rarely used among patients with AH. Only AH patients with generalized hyperhidrosis or palmoplantar hyperhidrosis are likely to receive oral anticholinergics.
miraDry is a non-invasive electromagnetic energy/microwave technology device that results in thermolysis of the sweat glands.
Additional treatment options for AH include local surgical procedures to remove the sweat glands including excision, curettage, liposuction, and laser.
Market report scope
Market size of US
(Year – 2020)
|Growth rate of US||CAGR of >15.0% from 2021 to 2025|
|Base year for estimation||2020|
This report provides a comprehensive analysis of the Axillary Hyperhidrosis market-
- Overview of AH including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline AH market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting AH therapeutics sales in the US.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the US AH therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are antiperspirants, anticholinergics, and neuromuscular blockades.
The main driver to growth in the AH market is the sales of high-priced neuromuscular blockades.
The main barrier to growth in the AH market is limited disease awareness that will continue to keep the diagnosis and treatment cases at a low rate.
The greatest unmet needs within the AH market are improved anticholinergic drug delivery systems, therapies causing longer-lasting neuromuscular blockade, increased awareness and education, and better insurance coverage for treatments.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the US AH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US AH market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the US AH therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Journey Medical Corporation
Table of Contents
Table of Contents (PowerPoint Deck)
1 Executive Summary
1.1 Executive Summary
2 Disease Overview
2.1 Overview of Axillary Hyperhidrosis
2.2 Axillary Hyperhidrosis SWOT Analysis
3.1 Lifetime Diagnosed Prevalent Cases of AH, 2020–2030
3.2 Age-Specific Prevalence of AH, 2020
3.3 Sources and Methodology
4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Treatment Algorithm
4.3 Marketed Products
4.4 Product Profile: Antiperspirants (aluminum chloride hexahydrate)
4.5 Product Profile: Journey Medical Corporation’s Qbrexza (glycopyrronium tosylate)
4.6 Product Profile: Allergan/AbbVie’s Botox (onabotulinumtoxin A)
4.7 Product Profile: Botulinum Toxin Drugs
4.8 Product Profile: Oral Anticholinergics
5 Unmet Needs and Opportunities
5.1 Unmet Needs in Axillary Hyperhidrosis
6 Pipeline Assessment
6.1 Leading Pipeline Agents
6.2 Product Profile: Brickell Biotech’s Ecclock (sofpironium bromide)
7 R&D Strategies
7.1 Trends in Clinical Trial Design in Axillary Hyperhidrosis
7.2 Trends in Deal-Making in Axillary Hyperhidrosis
8 Market Outlook
8.1 Axillary Hyperhidrosis Market Forecast
8.2 Impact of COVID-19 on Axillary Hyperhidrosis
8.3 Market Drivers and Barriers
9.2 Primary Research: KOL Information
9.3 About the Authors
10 Contact Us
Frequently asked questions
What is the value of the axillary hyperhidrosis market in the US for 2020?
The axillary hyperhidrosis market in the US was valued at $65.6 million in 2020.
What is the growth rate of the axillary hyperhidrosis market in the US?
The axillary hyperhidrosis market in the US is projected to grow at a CAGR of more than 15% during the forecast period 2021-2025.
Lifetime diagnosed prevalent cases were highest in which age group in the US?
In 2020, the lifetime diagnosed prevalent cases in the US peaked in the 20–29-year age group and gradually declined afterward through the 50–59-year age group.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.